Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic regimens in nonHodgkin's lymphoma (NHL) patients. The study included 72 patients with NHL (42 follicular and 30 large cells). The mean age was 37 years (range 17-60). Sixty-four patients (88.9%) had stage III-IV disease. Forty-eight patients (66.7%) had bone marrow involvement. Systemic B symptoms were present in 42 patients (58.3%). Mobilization chemotherapy regimens were randomly assigned as DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m 2 ) in 34 (47.2%) and the results of 132 procedures were analyzed. At the time of PBSC mobilization, 46 patients (63.9%) were considered to be responsive (complete remission, partial remission or sensitive relapse) and 26 (36.1%) not responsive (refractory relapse or refractory to therapy).
toxicity. [5] [6] [7] [8] In the literature, high-dose cyclophosphamide (CPM) seems to be the gold standard for mobilizing hematopoietic progenitor cells in lymphoproliferative disorders. 9, 10 Single high doses of alkylating agents (high-dose CPM or melphalan) have been used as mobilizing chemotherapy in NHL and other malignancies. [9] [10] [11] [12] Combination chemotherapy regimens such as DHAP or MAD or ESHAP have also been used for stem cell harvesting. [13] [14] [15] In a previous study the DHAP protocol has already shown real efficacy in debulking and in vivo purging in refractory or in partial remission NHL. 16, 17 The DHAP regimen was thus integrated into various treatment plans tailored for NHL patients as a second-line therapy and salvage chemotherapy for PR patients, or as an intensification and mobilizing regimen in CR high risk patients. 16, 17 In our previous experience, we used the DHAP protocol as salvage treatment in patients in PR or with refractory NHL. Few randomised studies report a comparison of mobilizing capacity of two different chemotherapeutic regimens such as ESHAP or ifosfamide vs CPM in lymphoproliferative disorders. [18] [19] [20] In our study 72 NHL patients undergoing PBSC transplantation were prospectively randomized to mobilize PBSC with the DHAP regimen or with high-dose CPM in order to evaluate whether there were any differences in the number of mononuclear cells harvested (× 10 
Patients and methods
The following parameters were examined in the two different mobilized groups: ( Patients were later assigned to mobilization chemo- ) in 34 (47.2%). All patients received G-CSF (lenogastrim) 5 g/kg/days from day +2 after chemotherapy. 13, 14 CPM was given in five pulses each at a dose of 1 g/m 2 by infusion over 1 h. DHAP was given according to the original protocol (cisplatin 100 mg/m 2 intravenously (i.v.) by continuous infusion over 24 h, followed by cytosine arabinoside in two pulses each at a dose of 2 g/m 2 given 12 h apart. Dexamethasone, 40 mg i.v., was given on days 1 to 4). 16 
Stem cell collection and cryopreservation procedure
Stem cell collection was performed with a Fenwal CS 3000 (Baxter-Fenwal Division, Deerfield, IL, USA). PBSC harvesting was started when a white blood count (WBC) Ͼ1 × 10 3 /l and Ͼ10/ml CD34 + cells were reached. The apheresis product of a 50 ml cell suspension was mixed with the same volume of minimal essential medium (MEM) containing 20% dimethylsulfoxide (DMSO) and stored at −196°C. For every bag harvested, mononucleated cells/kg, CD34 + cells/kg and CFU-GM/kg were evaluated at the end of each apheresis.
Flow cytometry assay for CD34
+ cell estimation Twenty l of whole blood were incubated for 30 min at 4°C with 10 ml of fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody HPCA2. The leukocyte population was analyzed by acquiring 3000 events using a Becton Dickinson (San Jose, CA, USA) FACScan with a two-watt argon ion laser as a light source. Excitation was allowed at 488 nm and fluorescence was measured at 530 nm. 21 
CFU-GM assay
The concentration of hematopoietic progenitor cells in each single leukapheresis product was assessed using a semisolid clonogenic culture assay. 2 × 10 5 /ml mononuclear cells were plated in duplicate and incubated at 37°C and 5% CO 2 in humidified atmosphere. After 14 days, colonies were scored using an inverted microscope. 22 
Engraftment speed
Engraftment speed was determined by the number of days necessary to reach ANC у0.5 × 10 9 /l and platelets у30 × 10 9 /l for at least 2 days. Engraftment speed was compared to the type of mobilization regimen and to the quantity of cells infused.
Statistical analysis
Descriptive statistics are presented as the median and range. The relationship between different hematological parameters of the peripheral blood and leukapheresis products was estimated by the non-parametric Spearman rank correlation. Comparisons between groups of the analyzed parameters were performed using the Student's t-test. A P value of Ͼ0.05 was considered significant. Table 2 Clinical and hematological parameters CHT = chemotherapy; CPM = cyclophosphamide; DHAP = cisplatin, cytosine arabinoside, dexamethasone; NS = not significant.
Results
Characteristics of patients in the two treatment groups (DHAP, CPM) were similar in terms of number of previous chemotherapy courses, time from diagnosis, time from last chemotherapy, number of apheresis procedures and volume processed ( Table 2) .
Collection phase
Seventy-two patients received either high-dose CPM (n = 34) or DHAP (n = 38) plus G-CSF as mobilization therapy and 132 leukapheresis procedures (63 in the CPM group and 69 in DHAP) were performed with a median of two leukapheresis (range 1-3) per patient ( Table 2) . No difference was found in terms of pre-apheresis CD34 + cell count. The mean number of CD34 + cells in the peripheral blood was 19/ml in the CPM group and 26/ml in the DHAP group ( Table 2 ). The mean number of MNC in the apheresis products was 2.9 × 10 + cells and CFU-GM collected between the two different mobilization schedules (Table 3) . 
Bone Marrow Transplantation

Clinical parameters
The age and number of previous chemotherapy treatments correlated in terms of CFU-GM (r = −0.5) and CD34 + cells/kg (r = −0.5) collected, independently of the mobilizing protocol (DHAP or CPM) (Figures 1 and 2 ). In the two groups examined, histology, disease status IPI and bone marrow involvement demonstrated no difference either in terms of MNC, CD34
+ cells or CFU-GM collected.
Hematological parameters
WBC count was found to correlate with the number of MNC collected (r = 0.4). We found no correlation between WBC count in the peripheral blood and the number of CD34 + cells in the peripheral blood or in the apheresis component.
The yield of CD34 + cells collected showed a strong correlation with the pre-apheresis CD34 + cell count in the peripheral blood. The correlation coefficient for the number of CD34 + cells in the peripheral blood with the number of CD34 + cells in the apheresis component was 0.4 ( Figure 3 ). 
Mobilization regimen toxicity
Grade I (WHO) nausea and vomiting was present in eight (21%) and in six (18%) patients in CPM and DHAP groups, respectively. Grade I hemorrhagic cystitis was observed in seven (18%) patients in the CPM group, grade 0 in DHAP. Grade I neurological complications and grade II acute renal failure occurred in six (18%) and in seven (21%) patients in the DHAP group, grade 0 in CPM. All of these complications were mild and reversible within 24-48 h in all cases.
Transplant phase
For all patients, the mean time to ANC у0.5 ϫ 10 9 /l was 10 days. The mean time to platelets у30 ϫ 10 9 /l was 12 days. The mean number of days to achieve an ANC у0.5 ϫ 10 9 /l was 10 for the DHAP group and nine for the CPM group. No statistically significant difference in ANC recovery was noted in the two mobilized groups ( Table 4 ). The mean number of days to reach a platelet count of у30 ϫ 10 9 /l, ignoring transfusions, for 3 days was 13 for the DHAP group and 10 for the CPM group. A statistically significant difference was noted (P = 0.022) in the two groups (Table 4) recovery, but did not correlate with PLT recovery ( Figure  4 ).
Discussion
Age, disease status, number of previous chemotherapy regimens, timing of harvest, disease status and type of mobilizing protocol may have various influences on the mobilizing potential of hematopoietic stem cells and precursor cells. [23] [24] [25] [26] Cytotoxic agents, with or without growth factor, are known to damage both hematopoietic and mesenchymal marrow stem cell compartments, thus suggesting that different chemotherapy agents might affect not only the quantity, but also the quality of mobilized progenitors. [27] [28] [29] [30] No definitive assessment exists concerning the best chemotherapy mobilizing regimen given with G-CSF. 31, 32 Hematological parameters including MNC or CD34
+ cell pre-apheresis counts can probably predict hematopoietic stem cell collection. Overall MNC collection efficiency, that is a measure of the percentage of the total available MNC collected, correlates with pre-apheresis WBC count. 31, 32 In the literature, various experiments describe the potential of different doses of CPM, ranging from 4 to 7 g/m 2 , to mobilize CD34 + cells. 10, 12 In this study, we utilized our previous experience of second-line treatment with the DHAP regimen for lymphomas patients in partial remission or with refractory or relapsing disease. DHAP is capable of effecting excellent debulking, confirming chemosensitive disease, suggesting that HDC and autologous stem cell transplantation could be used as salvage treatment. 13, 16, 17, 33 Little data concerning prospective randomized trials describe the mobilizing and collecting potential of different regimens such as ESHAP or ifosfamide vs CPM. [18] [19] [20] Since we use DHAP to treat NHL, we decided to compare high-dose CPM and DHAP in a random fashion in an attempt to demonstrate some kind of prognostic significance in terms of mobilization potential or toxicity.
Our data suggest on univariate analysis that the number of chemotherapy regimens and age have a negative influence on number of CD34 + cells and CFU-GM harvested, and not the two types of mobilizing regimen examined. No other clinical parameter (disease status, IPI and bone marrow involvement) influenced CD34
+ cell mobilizing potential. In our experience, the two mobilizing regimens have the same potential for collecting CD34
+ cells, CFU-GM and MNC. Otherwise, the number of CD34
+ cells in the peripheral blood positively correlated with CD34
+ numbers collected, but not with MNC or CFU-GM. Ten percent of patients who mobilized poorly had no correlation with age, disease, MNC or CD34 + cell number, and at the present time there are no data allowing prediction of such an unfavorable outcome.
Mild and reversible non-hematological toxicity, acute renal failure or grade II mucositis were more common in the DHAP group. CPM was associated with 18% of hemorrhagic cystitis. In the DHAP group, 18% of grade II neurological problems and 21% of grade II acute renal failures occurred. Engraftment was similar in the two treatment groups, as was long-term hematopoietic reconstitution. A statistical difference was noted for short-term platelet recovery, which was more rapid in CPM patients than in the DHAP group, but no data are reported in the literature to explain this; further studies are needed.
We obtained the same number of cells by each of the two mobilizing regimens in our series of patients. Since DHAP is an effective and well-tolerated treatment in NHL patients where second-line therapy is needed and since it is able to mobilize stem cells when followed by G-CSF, it seems that DHAP is useful as a mobilizing regimen for stem cell collection in patients with residual lymphoma and that it can be used as second-line therapy.
